dr. seymour on the pfs benefit with acalabrutinib with or without obinutuzumab in cll
Published 3 years ago • 72 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
14:31
side effects w/ acalabrutinib vs ibrutinib for chronic lymphocytic leukemia (cll) - dr. john seymour
-
1:05
dr seymour on the role of mutational profiling in cll
-
0:51
dr. seymour on role of ibrutinib in cll
-
13:19
side effects of acalabrutinib vs. ibrutinib in relapsed cll - dr. john seymour ash 2021
-
1:35
dr. seymour on updated findings from the murano trial in cll
-
8:10
continued benefit of acalabrutinib with or without obinutuzumab in cll - ash 2023
-
5:21
acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with cll
-
1:09
majic: venetoclax with acalabrutinib or obinutuzumab in cll
-
1:20
dr. woyach on 3-year follow-up of acalabrutinib/obinutuzumab combo in cll
-
1:10
dr. seymour on shifting standards of care in cll
-
1:50
dr. seymour on the 4-year update of the murano trial in cll
-
1:35
the safety and efficacy of tirabrutinib and entospletinib with or without obinutuzumab in r/r cll
-
8:55
elevate-tn: acalabrutinib ± obinutuzumab versus obinutuzumab chlorambucil in treatment-naïve c...
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:46
dr. al-sawaf on updated pfs data with venetoclax plus obinutuzumab in cll
-
4:53
elevate tn: comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment...
-
8:16
venetoclax and obinutuzumab in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll